What is DSIP (Delta Sleep-Inducing Peptide)

DSIP (Delta Sleep-Inducing Peptide) is a endogenous neuromodulatory nonapeptide studied in research for its ability to promote slow-wave sleep and modulate endocrine functions. It is intended exclusively for research use.

Regarding its chemical identity, DSIP has a molecular formula of C35H48N10O15 and a molecular weight of 848.89 g/mol. Its reported canonical sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include DSIP.

Product for research use.

Mechanism of action of DSIP

DSIP acts on the central nervous system, though its exact receptor is not fully classified. It is known to modulate the activity of GABAergic systems, reduce corticotropin-releasing factor (CRF), and suppress the production of somatostatin, leading to a state conducive to deep, delta-wave sleep.

Pharmacokinetics and pharmacodynamics of DSIP

DSIP crosses the blood-brain barrier relatively well for a peptide but is rapidly degraded by aminopeptidases in the blood, resulting in a short half-life of only a few minutes. Its sleep-inducing effects, however, outlast its presence in plasma.

Scientific evidence on DSIP

The available evidence on DSIP is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated for its potential to treat insomnia, opiate withdrawal, and chronic pain. In animal models, it significantly increases the duration of deep slow-wave sleep. Some discontinued human trials suggested benefits in stress regulation, but results were highly variable.

DSIP applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

DSIP protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for DSIP, so no trial schemes or quantities are specified.

The presentations of this product (Multiple variations (e.g. 5MG, 10MG, 15MG)) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of DSIP

As a general guideline for laboratory handling, lyophilized peptides such as DSIP are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the Multiple variations (e.g. 5MG, 10MG, 15MG) contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

DSIP Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented DSIP security profile

The documented safety information in open sources for DSIP is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

Due to its neuromodulatory effects, potential cardiovascular shifts (like mild hypotension) and altered endocrine responses (changes in cortisol or LH) are theoretical considerations. Prolonged disruption of sleep architecture is also a theoretical risk.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

DSIP in a comparative context

Unlike traditional sedatives (like benzodiazepines) that forcefully depress the CNS, DSIP acts as a regulatory peptide, promoting a natural sleep architecture without significant next-day sedation in animal models.

History and development of DSIP

First isolated in 1977 from the cerebral venous blood of rabbits induced into deep sleep. It generated immense interest as a natural sleep aid and stress regulator, though its clinical development was hampered by inconsistent results and delivery challenges.